Hand-Foot Skin Reaction (HFSR)
4
0
0
1
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
7 treatments under study, led by Nicotinic Acid Routine Care
Research Leaders
6 sponsors active, led by OnQuality Pharmaceuticals (USA) LLC
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
25.0%
1 terminated out of 4 trials
50.0%
-36.6% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction
A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions
Research Network
Common Treatments
- Nicotinic Acid Routine Care1
- Urea1
- Vehicle Ointment1
- Zinc Supplementation1
- Tazarotene1
Active Sponsors
- OnQuality Pharmaceuticals (USA) LLC1
- Bayer1
- Zhejiang University1
- First People's Hospital of Hangzhou1
- Gazi University1
Top Investigators
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
First People's Hospital of Hangzhou
Gazi University
Related Conditions
- Solid Tumor1